Compare NFE & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFE | NNNN |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 270.4M |
| IPO Year | 2018 | 2023 |
| Metric | NFE | NNNN |
|---|---|---|
| Price | $5.91 | $6.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 228.0K |
| Earning Date | 11-20-2026 | 10-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,504,037,000.00 | N/A |
| Revenue This Year | $108.26 | N/A |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $5.13 |
| 52 Week High | $16.90 | $51.33 |
| Indicator | NFE | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 43.64 |
| Support Level | $0.55 | $5.13 |
| Resistance Level | $16.90 | $6.95 |
| Average True Range (ATR) | 1.36 | 0.52 |
| MACD | -0.50 | 0.21 |
| Stochastic Oscillator | 4.39 | 66.48 |
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).